{"entity":{"id":"nct06662669","kind":"trial","name":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of gemcitabine and nab-paclitaxel in pancreatic cancer, run by Shanghai YingLi Pharmaceutical Co. Ltd., not yet recruiting.","summary":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer is a phase 1/2, randomised interventional study registered as NCT06662669 by Shanghai YingLi Pharmaceutical Co. Ltd., with a registry enrolment figure of 120 participants, started 2024-11-30 and due to reach its primary completion in 2027-09-30. Interventions recorded: YL-13027; HY-0102; Gemcitabine; Nab-paclitaxel. Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Objective response rate; Progression-free survival. Pancreatic eligibility wording from the registry: \"* Subject has histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06662669","url":"https://clinicaltrials.gov/study/NCT06662669"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06662669","phase":"1/2","setting":"A Randomized, Open, Parallel-controlled, Multi-center , Phase Ib/II Clinical Trial of YL-13027 and/or HY-0102 Combined With AG（Nab-paclitaxel and Gemcitabine) Regimen Chemotherapy for Metastatic Pancreatic Cancer","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06662669/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}